<DOC>
	<DOCNO>NCT01552005</DOCNO>
	<brief_summary>The purpose study respond The French Health Authority request BMS France Astra Zeneca ( AZ ) France set-up long-term cohort study representative sample French Type 2 Diabetes mellitus ( T2D ) patient treat Saxagliptin generate real world data drug utilization , joint population , non comparative effectiveness safety</brief_summary>
	<brief_title>Description Drug Utilization Assessment Impact Saxagliptin Health Status Patients With Type 2 Diabetes France</brief_title>
	<detailed_description>Time Perspective : Ambispective cohort follow 18 24 month follow period , Retrospective follow Prospective .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Registry Patient ≥ 18 year old Patient T2D Ambispective Cohort Patient ≥ 18 year old Patient T2D Patient initiate Saxagliptin last 6 month inclusion day inclusion visit ( whatever his/her ongoing hypoglycaemic treatment ) Patient agree participate , yet enrol another physician Patient participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>